Nishimura, Tomoyasu

写真a

Affiliation

Research Centers and Institutes, Health Center (Hiyoshi)

Position

Professor

External Links
Page Top ▲

Career 【 Display / hide 】

  • 2000.05
    -
    2002.04

    慶應義塾大学医学部, 内科学, 研修医

  • 2002.05
    -
    2004.05

    慶應義塾大学医学部, 内科学, 専修医

  • 2004.06
    -
    2010.01

    慶應義塾大学医学部, 内科学(呼吸器), 助手

  • 2007.01
    -
    2010.01

    慶應義塾大学医学部, 微生物学・免疫学, 研究員

  • 2008.07
    -
    2010.01

    佐野厚生総合病院, 内科, 医員

display all >>

Page Top ▲

Academic Background 【 Display / hide 】

  • 2000.03

    Keio University, Faculty of Medicine, 医学科

    University, Graduated

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士, Keio University, Dissertation, 2008.06

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 医師免許, 2000.04

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Respiratory medicine

  • Life Science / Infectious disease medicine

Page Top ▲

Research Keywords 【 Display / hide 】

  • Mycobacteriosis

Page Top ▲
 

Books 【 Display / hide 】

  • EBM呼吸器疾患の治療2016-2017

    Nishimura Tomoyasu, 中外医学社, 2016.01

    Scope: Interferon Gamma Release Assayの有用性は？

  • 新 呼吸器専門医テキスト

    Nishimura Tomoyasu, 南江堂, 2015.04

    Scope: 肺結核症

  • 内科研修マニュアル　改訂第2版

    Nishimura Tomoyasu, 南江堂, 2006.07

    Scope: 市中肺炎/院内肺炎

Page Top ▲

Papers 【 Display / hide 】

  • Factors affecting motivation for receiving a booster dose of the COVID-19 vaccine among Japanese university students and staff: a cross-sectional questionnaire survey

    Uchida S., Uno S., Kondo M., Uwamino Y., Namkoong H., Nishimura T., Misawa K., Kashimura S., Yamato K., Ishizaka T., Nagashima K., Kitagawa Y., Hasegawa N.

    Scientific Reports 14 ( 1 )  2024.12

    　View Summary

    Understanding the factors that influence people’s decisions regarding vaccination is essential to promote vaccination. We aimed to clarify the motivations for receiving booster vaccines. We conducted a paper-based questionnaire distributed during January–February 2022 involving students and faculty staff who received the first COVID-19 vaccination at the mass vaccination program during June–September 2021 at Keio University. A total of 1725 participants were enrolled, and all completed the survey. Among these, 64.9% reported a significant adverse event (AEs) affecting daily life after the second vaccine. “Fear of severe COVID-19 illness” (72.6%) was the most common reason for getting vaccinated, followed by “concern of infecting others” (68.4%) and “fear of COVID-19 infection itself” (68.3%). Television emerged as the most influential source of information (80%), followed by university information (50.2%) and social networking sites (42.8%). Multivariate analysis revealed “fear of severe COVID-19 illness”, “fear of COVID-19 infection itself”, and “trust in the efficacy and safety of the vaccines in general” were significantly correlated with willingness to receive paid vaccinations. The severity of AEs and source of information were not related to participants’ willingness to receive booster vaccinations. Participants with positive reasons for vaccination were more likely to accept a third dose.

  • Minimum inhibitory concentrations of azithromycin in clinical isolates of Mycobacterium avium complex in Japan

    Uwamino Y., Aoki W., Inose R., Kamoshita Y., Mikita K., Namkoong H., Nishimura T., Matsushita H., Hasegawa N.

    Microbiology Spectrum 12 ( 6 )  2024.06

    　View Summary

    The latest guidelines include azithromycin as a preferred regimen for treating Mycobacterium avium complex (MAC) pulmonary disease. However, serially collected susceptibility data on clinical MAC isolates are limited, and no breakpoints have been determined. We investigated the minimum inhibitory concentrations (MICs) of azithromycin and clarithromycin for all MAC strains isolated in 2021 from a single center in Japan, excluding duplicates. The MICs were determined using a panel based on the microbroth dilution method, according to the latest Clinical and Laboratory Standards Institute recommendations. The MICs were determined for 318 MAC strains. Although there was a significant positive correlation between the MICs of azithromycin and clarithromycin, the MICs of azithromycin tended to be higher than those of clarithromycin. Among the cases in which the strains were isolated, 18 patients initiated treatment, including azithromycin treatment, after sample collection. Some patients infected with stains with relatively high azithromycin MICs achieved a microbiological cure with azithromycin-containing regimens. This study revealed a higher MIC distribution for azithromycin than clarithromycin, raising questions about the current practice of estimating azithromycin susceptibility based on the clarithromycin susceptibility test result. However, this was a single-center study that included only a limited number of cases treated with azithromycin. Therefore, further multicenter studies that include a greater number of cases treated with azithromycin are warranted to verify the distribution of azithromycin MICs and examine the correlation between azithromycin MICs and treatment effectiveness. IMPORTANCE The macrolides serve as key drugs in the treatment of pulmonary Mycobacterium avium complex infection, and the administration of macrolide should be guided by susceptibility test results. Azithromycin is recommended as a preferred choice among macrolides, surpassing clarithromycin; however, drug susceptibility testing is often not conducted, and clarithromycin susceptibility is used as a surrogate. This study represents the first investigation into the minimum inhibitory concentration of azithromycin on a scale of several hundred clinical isolates, revealing an overall tendency for higher minimum inhibitory concentrations compared with clarithromycin. The results raise questions about the appropriateness of using clarithromycin susceptibility test outcomes for determining the administration of azithromycin. This study highlights the need for future discussions on the clinical breakpoints of azithromycin, based on large-scale clinical research correlating azithromycin susceptibility with treatment outcomes.

  • New polycyclic tetramate macrolactams with antimycobacterial activity produced by marine-derived Streptomyces sp. KKMA-0239

    Shigeno S., Kadowaki M., Nagai K., Hosoda K., Terahara T., Nishimura T., Hasegawa N., Tomoda H., Ohshiro T.

    Journal of Antibiotics 77 ( 5 ) 265 - 271 2024.05

    ISSN  00218820

    　View Summary

    During our screening for anti-mycobacterial agents against Mycobacterium avium complex (MAC), two new polycyclic tetramate macrolactams (PTMs), named hydroxycapsimycin (1) and brokamycin (2), were isolated along with the known PTM, ikarugamycin (3), from the culture broth of marine-derived Streptomyces sp. KKMA-0239. The relative structures of 1 and 2 were elucidated by spectroscopic data analyses, including 1D and 2D NMR. Furthermore, the absolute configuration of 1 was confirmed by a single-crystal X-ray diffraction analysis. Compounds 2 and 3 exhibited moderate antimycobacterial activities against MAC, including clinically isolated drug-resistant M. avium.

  • Mavintramycin A is a promising antibiotic for treating Mycobacterium avium complex infectious disease

    Hosoda K., Koyama N., Shigeno S., Nishimura T., Hasegawa N., Kanamoto A., Ohshiro T., Tomoda H.

    Antimicrobial Agents and Chemotherapy 68 ( 3 )  2024.03

    ISSN  00664804

    　View Summary

    Mycobacterium avium complex (MAC) is a serious disease that is mainly caused by infection with the non-tuberculous mycobacteria (NTM), Mycobacterium avium and Mycobacterium intracellulare. Seven new compounds, designated mavintramycins A–G (1–7), were isolated along with structurally related compounds, including amicetin (9) and plicacetin (10), from the culture broth of Streptomyces sp. OPMA40551 as anti-MAC compounds that were active against M. avium and M. intracellulare. Among them, mavintramycin A showed the most potent and selective inhibition of M. avium and M. intracellulare. Furthermore, mavintramycin A was active against more than 40 clinically isolated M. avium, including multidrug-resistant strains, and inhibited the growth of M. avium in a persistent infection cell model using THP-1 macrophages. Mavintramycin A also exhibited in vivo efficacy in silkworm and mouse infection assays with NTM. An experiment to elucidate its mechanism of action revealed that mavintramycin A inhibits protein synthesis by binding to 23S ribosomal RNA in NTM. Mavintramycin A, with a different chemical structure from those of clinically used agents, is a promising drug candidate for the treatment of MAC infectious disease.

  • Gastrointestinal symptoms in COVID-19 and disease severity: a Japanese registry-based retrospective cohort study

    Matsubara Y., Kiyohara H., Mikami Y., Nanki K., Namkoong H., Chubachi S., Tanaka H., Azekawa S., Sugimoto S., Yoshimatsu Y., Sujino T., Takabayashi K., Hosoe N., Sato T., Ishii M., Hasegawa N., Okada Y., Koike R., Kitagawa Y., Kimura A., Imoto S., Miyano S., Ogawa S., Fukunaga K., Kanai T., Chubachi S., Fukushima T., Lee H., Otake S., Nakagawara K., Morita A., Watase M., Sakurai K., Ogawa T., Kusumoto T., Masaki K., Kabata H., Ikemura S., Okamori S., Terai H., Kamata H., Uchida S., Uno S., Hasegawa N., Takahashi K., Sasano H., Harada N., Takagi H., Nakamura A., Naito T., Hiki M., Matsushita Y., Aoki R., Harada S., Sasaki J., Morisaki H., Uwamino Y., Mikami Y., Ishihara R., Nishimura T., Sato T., Ueda T., Azuma M., Saito R., Sado T., Miyazaki Y., Sato R., Haruta Y., Nagasaki T., Hasegawa Y., Yasui Y., Ueda S., Tada A., Miyawaki M., Yamamoto M., Yoshida E., Hayashi R., Nagasaka T., Arai S., Kaneko Y., Sasaki K., Ishiguro T., Isono T., Shibata S., Matsui Y., Hosoda C., Takano K., Nishida T., Kobayashi Y., Takaku Y., Takayanagi N., Tagaya E.

    Journal of Gastroenterology 59 ( 3 ) 195 - 208 2024.03

    ISSN  09441174

    　View Summary

    Background: Research on whether gastrointestinal symptoms correlate with the severity of Coronavirus Disease 2019 (COVID-19) has been inconclusive. This study aimed to clarify any associations between gastrointestinal symptoms and the prognosis of COVID-19. Methods: We collected data from the Japanese nationwide registry for COVID-19 to conduct a retrospective cohort study. Data from 3498 Japanese COVID-19 patients, diagnosed at 74 facilities between February 2020 and August 2022, were analyzed in this study. Hospitalized patients were followed up until discharge or transfer to another hospital. Outpatients were observed until the end of treatment. Associations between gastrointestinal symptoms and clinical outcomes were investigated using multivariable-adjusted logistic regression models. Results: The prevalence of diarrhea, nausea/vomiting, abdominal pain, and melena were 16.6% (581/3498), 8.9% (311/3498), 3.5% (121/3498), and 0.7% (23/3498), respectively. In the univariable analysis, admission to intensive care unit (ICU) and requirement for mechanical ventilation were less common in patients with diarrhea than those without (ICU, 15.7% vs. 20.6% (p = 0.006); mechanical ventilation, 7.9% vs. 11.4% (p = 0.013)). In the multivariable-adjusted analysis, diarrhea was associated with lower likelihood of ICU admission (adjusted odds ratio (aOR), 0.70; 95% confidence interval (CI), 0.53–0.92) and mechanical ventilation (aOR, 0.61; 95% CI, 0.42–0.89). Similar results were obtained in a sensitivity analysis with another logistic regression model that adjusted for 14 possible covariates with diarrhea (ICU; aOR, 0.70; 95% CI, 0.53–0.93; mechanical ventilation; aOR 0.62; 95% CI, 0.42–0.92). Conclusions: Diarrhea was associated with better clinical outcomes in COVID-19 patients.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • 外国人留学生を対象とした結核感染調査

    西村知泰，森正明，牧野伸司，広瀬寛，和井内由充子，横山裕一，武田彩乃，畔上達彦，後藤伸子，河邊博史

    第116回日本内科学会総会・講演会 (名古屋) , 

    2019.04
    , 

    Poster presentation

  • 肺MAC症の新規検査法

    Nishimura Tomoyasu

    第101回日本細菌学会関東支部総会 (東京) , 

    2018.11
    , 

    Symposium, workshop panel (nominated)

  • アスペルギルス沈降抗体陽性である肺Mycobacterium avium complex症患者の臨床的特徴

    鈴木翔二, 朝倉崇徳, 南宮湖, 岡森慧, 八木一馬, 鎌田浩史, 舩津洋平, 中野泰, 西村知泰, 石井誠, 海老原全, 別役智子, 長谷川直樹．

    第58回日本呼吸器学会学術講演会 (大阪) , 

    2018.04
    , 

    Poster presentation

  • 大学生における先天性心疾患の管理状況

    牧野伸司, 和井内由充子, 武田彩乃, 畔上達彦, 広瀬寛, 西村知泰, 横山裕一, 河邊博史, 森正明．

    第115回日本内科学会年次学術講演会 (京都) , 

    2018.04
    , 

    Poster presentation

  • 当大学医学部留学生に対するImmunization Recordの運用と考察

    武藤志保, 横山裕一, 弦巻美保, 齋藤圭美, 西村知泰, 森正明, 河邊博史．

    第55回全国大学保健管理研究集会 (宜野湾) , 

    2017.11
    , 

    Poster presentation

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • 慶應義塾の健康関連データベースを用いた、健康問題発生における危険因子の探索

    2025.04
    -
    2026.03

    福澤基金研究補助, Research grant, Principal investigator

  • 難治性肺非結核性抗酸菌症の新規薬物治療法開発

    2025.01
    -
    2026.12

    公益財団法人 シオノギ感染症研究振興財団, 創薬研究助成金, Research grant, Principal investigator

  • 新規肺MABC症治療薬の開発と革新的非臨床PK/PD評価法の構築

    2024.04
    -
    2028.03

    文部科学省・日本学術振興会, 科学研究費補助金, Research grant, Coinvestigator(s)

  • 難治性肺非結核性抗酸菌症の新規薬物治療法開発

    2024.01
    -
    2024.12

    公益財団法人 シオノギ感染症研究振興財団, 萌芽的研究助成金, Research grant, Principal investigator

  • 肺MAC症の新規治療法開発に向けた菌細胞壁脂質の解析

    2023.04
    -
    2026.03

    文部科学省・日本学術振興会, 科学研究費補助金, Research grant, Principal investigator

display all >>

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • MEDICINE IN MODERN SOCIETY 2

    2025

  • MEDICINE IN MODERN SOCIETY 1

    2025

  • INFECTIOUS DISEASES

    2025

  • MEDICINE IN MODERN SOCIETY 1

    2024

  • INFECTIOUS DISEASES

    2024

display all >>

Page Top ▲

Courses Previously Taught 【 Display / hide 】

  • 現代社会と医学Ⅱ

    Keio University

    2018.04
    -
    2019.03
    , 

    Full academic year, Other, Lecture, Within own ｆaculty

  • 感染症学

    Keio University

    2018.04
    -
    2019.03
    , 

    Full academic year, Other, Lecture, Lecturer outside of Keio

Page Top ▲
 

Social Activities 【 Display / hide 】

  • 平成27年度外務省巡回医師団

    2016.02
    -
    2016.03

  • 平成26年度外務省巡回医師団

    2015.01
    -
    2015.02
Page Top ▲

Memberships in Academic Societies 【 Display / hide 】

  • 日本免疫学会

    　

  • 日本内科学会

    　

  • 日本呼吸器学会

    　

  • 日本呼吸器内視鏡学会

    　

  • 日本感染症学会

    　

display all >>

Page Top ▲

Committee Experiences 【 Display / hide 】

  • 2016.04
    -
    Present

    評議員, 日本感染症学会

Page Top ▲